S025 JAK Inhibitors: A New Frontier in Dermatology
DESCRIPTION
Janus kinase (JAK) inhibitors are a new class of medicine in dermatology and are increasingly important due to their unmatched therapeutic potential across inflammatory skin diseases. The application of JAK inhibitors to dermatologic diseases will be presented, including the results of clinical trials and case series. The safety profile of JAK inhibitors will be discussed in detail. The audience for this session will be dermatologists who care for patients with alopecia areata, atopic dermatitis and prurigo nodularis and pruritus, granuloma annulare and sarcoidosis, lichen planus, lichen planopilaris, lupus and dermatomyositis and other CTD, hidradenitis suppurativa, and vitiligo.
LEARNING OBJECTIVES
Describe a new and important class of medications in dermatology.
Utilize JAK inhibitors for the treatment of alopecia areata, atopic dermatitis, dermatomyositis, granuloma annulare and sarcoidosis, hidradenitis suppurativa, lichen planus, lupus, pruritus, and vitiligo.
Summarize the safety profile of JAK inhibitors and differentiate the safety profile among disease states.
SCHEDULE
9:00 AM
Why JAK Inhibitors are so Broadly Effective
Brett King, MD, PhD, FAAD
9:10 AM
JAK Inhibitors for Vitiligo
George Han, MD, PhD, FAAD
9:25 AM
JAK Inhibitors for Dermatomyositis, Lupus, and SAVI
Ruth Ann Vleugels, MD, MBA, MPH, FAAD
9:40 AM
Q&A
George Han, MD, PhD, FAAD, Ruth Ann Vleugels, MD, MBA, MPH, FAAD
9:50 AM
JAK Inhibitors for Sarcoidosis and Granuloma Annulare
Avrom Caplan, MD, FAAD
10:05 AM
Hidradenitis Suppurativa and Pyoderma Gangrenosum
Martina J Porter, MD, FAAD
10:20 AM
Q&A
Avrom Caplan, MD, FAAD, Martina J Porter, MD, FAAD
10:30 AM
JAK Inhibitors for Lichen Planus and Lichen Planopilaris
Tiffany Mayo, MD, FAAD
10:45 AM
JAK Inhibitors for Alopecia Areata
Brittany Craiglow, MD, FAAD
11:00 AM
Q&A
Brittany Craiglow, MD, FAAD, Tiffany Mayo, MD, FAAD
11:10 AM
JAK Inhibitors for Atopic Dermatitis, Prurigo Nodularis, and Pruritus
Eric Lawrence Simpson, MD, FAAD
11:30 AM
Understanding the Safety Profile of JAK Inhibitors
Brett King, MD, PhD, FAAD
11:50 AM
Q&A
Brett King, MD, PhD, FAAD, Eric Lawrence Simpson, MD, FAAD
DIRECTOR
Brett King, MD, PhD, FAAD
SPEAKER
Tiffany Mayo, MD, FAAD
DISCLOSURES
Brett King, MD, PhD, FAAD
AbbVie – Advisory Board(Honoraria), Speaker(Honoraria); Amgen – Consultant (1099 relationship)(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Aquestive Therapeutics – Consultant (1099 relationship)(Fees); BiologicsMD, Inc. – Consultant(Stock Options); Bristol-Myers Squibb – Advisory Board(Honoraria), Consultant(Fees); Eli Lilly and Company – Consultant(Fees), Investigator(Fees), Speaker(Honoraria); Galderma – Advisory Board(Honoraria); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria), Consultant(Fees), Data Safety Monitoring Board(Fees); Leo Pharma – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Fees), Advisory Board(Honoraria), Consultant(Fees), Investigator(Fees), Speaker(Honoraria); Q32 Bio Inc. – Consultant (1099 relationship)(Fees); Regeneron – Advisory Board(Honoraria), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria), Consultant (1099 relationship)(Fees); Sanofi Genzyme – Speaker(Honoraria); Soterios Pharma – Consultant (1099 relationship)(Fees); Sun Pharmaceutical Industries Ltd. – Consultant(Fees), Investigator(Fees); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); TWi Biotechnology, Inc. – Consultant(Fees);
Tiffany Mayo, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria); Acelyrin – Investigator(Grants/Research Funding); Arcutis Biotherapeutics – Advisory Board(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); ChemoCentryx – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding); Galderma – Investigator(Grants/Research Funding); Incyte – Investigator(Grants/Research Funding); ITB-MED – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Leo Pharma – Advisory Board(Honoraria); Merck – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Oruka Therapeutics – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Procter & Gamble Company – Investigator(Grants/Research Funding); Sanofi – Advisory Board(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria);